Abstract

C. albicans is the most prevalent opportunistic fungal and can cause life-threatening systemic infections under certain circumstances. The inefficiency and resistance of traditional therapy make the development of novel techniques indispensable. The main components, proteins and glycoproteins, of the C. albicans cell wall are highly immunogenic and very different from those of the host, making it an ideal source of targets for antifungal drug development. This study aimed to screen and identify specific peptides that bind to the C. albicans cell wall using a phage-display peptide library, and to develop a peptide-based therapy targeted to C. albicans. After four rounds of screening, JC-1 ScFv was found to bind to the C. albicans cell wall specifically, inhibit C. albicans growth and viability in vitro, and protect mice from C. albicans infection in vivo. Further study showed that JC-1 could provoke an immune response in C. albicans-infected mice. These results indicated that JC-1 ScFv screened from a phage-display peptide library had the potential to be developed as a vector for targeting C. albicans.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.